Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 56, Issue 12, 2007, Pages 3940-3948

  Mattey, Derek L ^a,b,c   Glossop, John R ^a,b   Nixon, Nicola B ^a,b   Dawes, Peter T ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c HAYWOOD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CARDIOVASCULAR AGENT; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RHEUMATOID ARTHRITIS; ROC CURVE; SURVIVAL RATE;

AGED; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; ROC CURVE;

EID: 37149020708     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23075     Document Type: Article

References (49)

1. Symmons DP. Mortality in rheumatoid arthritis. Br J Rheumatol 1988;27 Suppl 1:44-54.
2. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
3. Chehata JC, Hassell AB, Clarke SA, Mattey DL, Jones MA, Jones PW, et al. Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) 2001;40:447-52.
4. Mikuls TR, Saag KG, Criswell LA, Merlino LA, Kaslow RA, Shelton BJ, et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the IOWA Women's Health Study. Ann Rheum Dis 2002;61:994-9.
5. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
6. Wallberg-Jonsson S, Ohman ML, Rantapaa-Dahlqvist S. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24: 445-51.
7. Wallberg Jonsson S, Ohman ML, Johansson H, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. J Rheumatol 1999;26:2562-70.
8. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32.
9. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107: 1303-7.
10. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005;64:1595-601.
11. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005;52:2293-9.
12. Brennan FM, Maini RN, Feldmann M. TNFα - a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992:31:293-8.
13. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
14. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990:223:236-41.
15. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92: 1479-86.
16. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-11.
17. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
18. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001;103:2055-9.
19. Orus J, Roig E, Perez-Villa F, Pare C, Azqueta M, Filella X, et al. Prognostic value of serum cytokines in patients with congestive heart failure. J Heart Lung Transplant 2000;19:419-25.
20. Aderka D, Engelmann H, Shemer-Avni Y, Hornik V, Galil A, Sarov B, et al. Variations in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res 1992;11:157-9.
21. Masson S, Latini R, Bevilacqua M, Vago T, Sessa F, Torri M, et al. Within-patient variability of hormone and cytokine concentrations in heart failure. Pharmacol Res 1998;37:213-7.
22. Dibbs Z, Thornby J, White BG, Mann DL. Natural variability of circulating cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 1999;33: 1935-42.
23. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-9.
24. Barrera P, Boerbooms AN, Janssen EM, Sauerwein RW, Gallati H, Mulder J, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993,36:1070-9.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
26. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
27. Guidelines and audit measures for the specialist supervision of patients with rheumatoid arthritis; report of the Joint Working Group of the British Society of Rheumatology and the Research Unit of the Royal College of Physicians. J R Coll Physicians Lond 1992;26:76-82.
28. International classification of diseases, ninth revision. Geneva: World Health Organization; 1977.
29. Larsen A. Radiological grading of rheumatoid arthritis: an interobserver study. Scand J Rheumatol 1973;2:136-8.
30. Zoppini G, Faccini G, Muggeo M, Zenari L, Falezza G, Targher G. Elevated plasma levels of soluble receptors of TNF-α and their association with smoking and microvascular complications in young adults with type 1 diabetes. J Clin Endocrinol Metab 2001;86:3805-8.
31. Fernandez-Real JM, Broch M, Vendrell J, Ricart W. Smoking, fat mass and activation of the tumor necrosis factor-α pathway. Int J Obes Relat Metab Disord 2003;27:1552-6.
32. Glossop JR, Dawes PT, Mattey DL. Association between cigarette smoking and release of tumour necrosis factor α and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:1223-9.
33. Valgimigli M, Ceconi C, Malagutti P, Merli E, Soukhomovskaia O, Francolini G, et al. Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) Study. Circulation 2005;111:863-70.
34. Cannon PJ, Connell PA, Stockley IH, Garner ST, Hampton JR. Prevalence of angina as assessed by a survey of prescriptions for nitrates. Lancet 1988;64:979-81.
35. Book C, Saxne T, Jacobsson LT. Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol 2005;32:430-4.
36. Winzen R, Wallach D, Kemper O, Resch K, Holtmann H. Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. J Immunol 1993;150: 4346-53.
37. Porteu F, Hieblot C. Tumor necrosis factor induces a selective shedding of its p75 receptor from human neutrophils. J Biol Chem 1994;269:2834-40.
38. Higuchi M, Aggarwal BB. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol 1994;152: 3550-8.
39. Cope AP, Gibbons DL, Aderka D, Foxwell BM, Wallach D, Maini R, et al. Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. Cytokine 1993;5:205-12.
40. Martel-Pelletier J, Mineau F, Jolicoeur FC, Pelletier JP. Modulation of TNFSR55 and TNFSR75 by cytokines and growth factors in human synovial fibroblasts. J Rheumatol Suppl 1995;43:115-9.
41. Galve-de Rochemonteix B, Nicod LP, Dayer JM. Tumor necrosis factor soluble receptor 75: the principal receptor form released by human alveolar macrophages and monocytes in the presence of interferon γ. Am J Respir Cell Mol Biol 1996;14:279-87.
42. Alsalameh S, Mattka B, Al-Ward R, Lorenz HM, Manger B, Pfizenmaier K, et al. Preferential expression of tumor necrosis factor receptor 55 (TNF-R55) on human articular chondrocytes: selective transcriptional upregulation of TNF-R75 by proinflammatory cytokines interleukin 1β, tumor necrosis factor-α, and basic fibroblast growth factor. J Rheumatol 1999;26:645-53.
43. Glossop JR, Dawes PT, Nixon NB, Mattey DL. Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble TNF receptors in rheumatoid arthritis. Arthritis Res Ther 2005;7:R1227-34.
44. Canault M, Peiretti F, Kopp F, Bonardo B, Bonzi MF, Coudeyre JC, et al. The TNF α converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF α receptors. Atherosclerosis 2006;187:82-91.
45. Satoh M, Nakamura M, Saitoh H, Satoh H, Maesawa C, Segawa I, et al. Tumor necrosis factor-α-converting enzyme and tumor necrosis factor-α in human dilated cardiomyopathy. Circulation 1999;99:3260-5.
46. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
47. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109: 1594-602.
48. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11.
49. Jacobsson LT, Turesson C, Nilsson JA, Petersson I, Lindqvist E, Saxne T, et al. Treatment with TNF-blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-5.